Calico team publishes on vanishing white matter disease

In a paper published in eLife, researchers from Calico Life Sciences LLC (South San Francisco, Calif.) and AbbVie Inc. (NYSE:ABBV) suggested that activating eukaryotic translation initiation factor 2B (EIF2B) could help treat vanishing

Read the full 339 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE